With the current increase in interest in commercially available APOE-genetic screening tests [45], like 23andMe, and associated requests to explain genetic results [58], and growing demand of personalised dementia risk reduction [56], the need for accurate education about genetic risk and disclosure impact arises. Here, APOE is linked to dementia.